Intramuscular iron-dextran and susceptibility of neonates to bacterial infections. In vitro studies

Area of Science:

• Neonatal Immunology
• Infectious Disease Pathogenesis
• Hematology

Background:

• Increased incidence of E. coli sepsis observed in neonates receiving intramuscular iron-dextran.
• Iron deficiency prevention in neonates is crucial, but parenteral iron administration requires careful consideration of potential adverse effects.

Purpose of the Study:

• To investigate the mechanisms underlying the apparent increased susceptibility to E. coli infection following intramuscular iron-dextran administration in neonates.
• To compare phagocytic and antibacterial functions in infant blood samples before and after iron-dextran treatment.

Main Methods:

• Paired venous blood samples were collected from 7 neonates (median age 5 days) before and after intramuscular iron-dextran administration.
• In vitro assays were performed to assess leucocyte chemotaxis and serum bacteriostatic effects against E. coli.

Main Results:

• Post-treatment sera exhibited increased inhibitory effects on leucocyte chemotaxis.
• Markedly reduced bacteriostatic effects against E. coli were observed in sera after iron-dextran treatment.
• The reduction in serum bacteriostasis is comparable to that seen in hyperferraemia not associated with transferrin saturation.

Conclusions:

• Parenteral iron-dextran administration in early infancy may compromise the infant's immune response, specifically reducing serum bacteriostatic activity against E. coli.
• The observed reduction in bacteriostasis is a likely contributor to the increased susceptibility to infection in vivo.
• Prophylactic treatment with parenteral iron-dextran is contraindicated in early infancy due to potential increased infection risk.